Abstract Most commercial HIV-1 genotyping assays are hampered by high cost in resource-limited settings. Moreover, their performance might be influenced over time by HIV genetic heterogeneity and evolution. An in-house genotyping protocol was developed, and its sequencing performance and reproducibility were compared to that of ViroSeq TM . One hundred ninety plasma samples from HIV-1-infected subjects in Cameroon, a resource-limited setting with a high HIV genetic variability, were processed for pol gene sequencing with an in-house protocol, ViroSeq TM , or both. Only non-B subtypes were found. The in-house sequencing performance was 98.7% against 92.1% with ViroSeq TM . Among 36 sequence pairs obtained using both assays, the overall rate of discordant amino acid positions was negligible (0.24%). With its high sensitivity and reproducibility, as well as its affordable cost (about half of ViroSeq TM : 92 € vs. 217 €), this in-house assay is a suitable alternative for HIV-1 genotyping in resource-limited and/or in high-genetic-diversity settings.
Introduction
Human immunodeficiency virus (HIV) infection remains a major global health priority, with about 33.4 millions [31. 1-35.8 ] people infected worldwide [1] . Even though access to antiretroviral therapy has helped in decreasing its morbidity and mortality, the rate of HIV-1 infection is still very high in sub-Saharan Africa (70%), where access to appropriate healthcare is limited by socio-economical factors [2] [3] [4] . With the increasing treatment possibilities, the evaluation of transmitted and acquired strains that are resistant to available antiviral drugs has become essential for sub-Saharan countries [5] . HIV-1 genotypic drug resistance testing (GRT) is considered an important basic tool to guide the choice of antiretroviral therapy in the European and North American countries. For this reason, the guidelines recommend genotypic resistance testing both in antiretroviral naïve patients and in patients with suboptimal virological responses or virologic failure [6, 7] .
By contrast, the World Health Organization (WHO) recommends the performance of GRT only for the surveillance of transmitted and acquired drug resistance in resource-limited settings. [5] Although patients in Cameroon have been receiving free highly active antiretroviral therapy (HAART) since 2007, the management of HIV infection within the health care system is still of poor quality due to insufficient and generic treatment guidelines, financial restrictions to individual patient follow-up and setbacks in diagnostics due to the high viral genetic variability [8, 9] . Cameroon is a setting where all of the known groups of HIV-1, the rare group O (Outlier), group N (Non-O, Non-M), and the recent group P, have been identified from people with epidemiologic links to this country [10] [11] [12] . Therefore, this country is a field setting with features that are suitable for assessing the performance of a genotyping tool that could be useful for HIV-1 GRT at an affordable cost, in order to improve the management of infected patients in health systems with similar characteristics. HIV-1 epidemiology in this country is reported to be stable, from 5.5% in 2004 to an estimate of 5.1% in 2009, for a total of 558,228 people living with HIV/acquired immunodeficiency deficiency syndrome (AIDS). With a rapid scaling-up to antiretroviral therapy (1.3% in 2003 to 50% in 2009), at least 76,228 patients are under HAART, including 3,114 children and 51,032 women in the entire national territory [13] . In this context, drug resistance testing is gradually becoming an indispensable tool for the surveillance and prevention of emerging resistant viral strains as well as for individualised patient monitoring [5, 14] . Most genotyping methods detect HIV drug resistance by nucleic acid sequencing in the protease (PR) and reverse transcriptase (RT) regions of the pol gene [15] [16] [17] . Two genotyping methods, approved by the Food and Drug Administration (FDA), ViroSeq TM HIV-1 Genotyping Version 2.7 from Celera Diagnostics, Alameda, CA, USA [18] [19] [20] , and TruGene [21] are currently available commercially. Interestingly, it should be considered that viral dynamics (due to the high error rate of RT), evolution over time (due to the high levels of HIV-1 replication), and the large spread of non-B subtypes might influence the overall performance of the existing genotyping tools [22] . Improved sensitivity of in-house sequencing assays compared to these commercially available kits has been reported by several laboratories, especially for some non-B subtypes [23] [24] [25] . These established in-house genotyping assays were designed in order to overcome cost and subtype-specific constraints [26, 27] . However, the performance of these in-house assays has not been validated against internationally approved reference systems [28, 29] , except for two recent ones, developed for subtypes B, C, and D circulating in India, and subtype C circulating in West and South Africa [24, 25] .
The main findings regarding HAART (highly active antiretroviral therapy) resistance in Cameroon were generally based on the ViroSeq TM genotyping system [30] [31] [32] , with the exception of an affordable in-house assay proven to be sensitive for the combined detection of plasma HIV-1 and assessment of drug resistance. Nevertheless, this inhouse method has never been compared to FDA-approved assays in terms of sequencing performance and the reproducibility of its mutation profile [27] . For the above reasons, the aim of this work was to develop and validate a reproducible, highly sensitive and affordable genotyping protocol for drug resistance surveillance and/or individualized monitoring in a context of high viral genetic diversity and limited resources. This would significantly improve the clinical management of patients infected with genetically different HIV-1 strains living in the sub-Saharan areas as well as in other developing countries.
Materials and methods

Study population
One hundred ninety plasma samples were collected from different HIV- All the samples were subjected to HIV-1 GRT, with the addition of ViroSeq TM -positive and negative standards used as quality control for every reaction. With the exception of three samples with a viral load above the limit of detection ([7 log 10 RNA copies/ml), the overall mean plasma viral load was 5.67 (min-max: 1.79-6.96) log 10 RNA copies/ml. Of these samples, 156/190 were processed with the in-house genotyping assay, and 76/190 with ViroSeq TM . The average viremia of samples tested with each protocol was nearly identical (in-house assay: 5.70 log 10 RNA copies/ml; Viroseq TM : 5.69 log 10 RNA copies/ml; min-max for both protocols: 1.79-6.96 log 10 RNA copies/ ml). Of all of the samples tested, only three indicated viremia \3 log 10 RNA copies/ml (1.79, 2.02, 2.48); all of them were processed with the in-house assay while two of them (viremia: 1.79, 2.48) were processed with the ViroSeq TM kit. Thirty-six samples were successfully processed by both methods and thereby used to evaluate the genotypic concordance between the two assays. The number of samples processed depended on the plasma availability in the bio-bank and on the stock of reagents available for each of the assays.
Four milliliters of whole blood was collected in ethylenediaminetetraacetic acid (EDTA) tubes. Two plasma aliquots of 1 ml each were constituted from every blood sample by centrifugation at 1800 rpm for 15 min and stored between ?2 and ?8°C for 24 hours or at -80°C for 6 months.
RNA extraction
Viral RNA was extracted from a one-milliliter aliquot of plasma and from the ViroSeq TM -positive and negative standards using a QIAamp Viral RNA Mini Kit (QIAGEN) according to the protocol specifications. The choice of using 1 milliliter of plasma for testing instead of 500 microliters as recommended for the ViroSeq TM kit was for the purpose of increasing the amount of extracted RNA and ensuring comparable results with both assays. HIV-RNA was processed directly for reverse transcription and amplification.
Reverse transcription and PCR amplification RNA extracts from patients and from the ViroSeq TM standards (positive and negative) were amplified using the ViroSeq TM protocol following the manufacturer's instructions (Celera Diagnostics, Alameda, CA, USA). The RNA extracts were also amplified following the developed inhouse RT polymerase chain reaction (RT-PCR) protocol. This protocol is a two-step PCR, and the primers were Both the ViroSeq TM kit and the in-house protocol, which were regularly performed alongside a negative PCR control, showed no problem of cross-contamination. For the in-house protocol, an additional negative control was run for the semi-nested-PCR. PCR products were analyzed by 1% agarose gel electrophoresis by visual comparison of the amount of PCR product with a low-molecular-weight DNA ladder included in the ViroSeq TM kit. The resulting amplicon encompassing the PR-RT region (approximately 1.5 kilobases in length) was purified using a Microcon YM-100 microconcentrator (Millipore).
Sequencing reaction
The amplified products from the pol region were completely sequenced in the sense and antisense orientations using an automated sequencer (ABI 3130 Genetic Analyzer) with seven different overlapping sequence-specific primers: 5' AGC AGA CCA GAG CCA ACA GC 3'(2140-2159 gag), 5' CCA TCC ATT CCT GGC TTT AAT 3' (2582-2602 pol), 5' CAG GAA TGG ATG GCC CAA AA 3' (2590-2609 pol), 5' TTG TAC AGA AAT GGA AAA GGA AGG 3' (2660-2683 pol), 5' CCC TGT GGA AAG CAC ATT GTA 3' (2985-3004, with an insertion), 5' GCT TCC ACA GGG ATG GAA A 3' (2993-3011 pol), 5' CTA TTA AGT CTT TTG ATG GGT CA 3' (3506-3528 pol) (with reference to the HXB2 strain from the Los Alamos National Laboratory database using the Sequence Locator and QuickAlign tools: http://www.hiv.lanl.gov/content/ sequence/HIV/mainpage.html). These sequencing primers were designed based on the analysis of highly conserved regions among HIV-1 subtypes. The reaction mixture for the sequencing reaction contained 8 ll ABI PRISM Big Dye Terminator (Perkin-Elmer), 4.8 ll water, 3.2 ll primer (1 pmol) and 4 ll of purified cDNA (40 ng), for a total volume of 20 ll. The sequencing conditions were as follows: 35 cycles (96°C, 10 s; 55°C, 10 s; 60°C, 4 min); 1 cycle of 4°C for 30 min. The quality of each sequence was ensured by covering the PR-RT region with at least two sequence segments (one forward and one reverse). The sequencing product was purified by gel filtration chromatography using Sephadex G-50 resin (Sigma-Aldrich) in order to eliminate excess primers, unincorporated dideoxynucleotides (ddNTPs), and salts.
Sequence analysis and detection of mutations Sequence data were obtained, and complete sequences encompassing the pol region of interest were assembled and manually edited using Seqscape version 2.5. All HIV-1 pol sequences (&1,197 nucleotides) were aligned in BioEdit version 5.0.6 using CLUSTAL W [33] and compared to reference sequences for the major HIV-1 subtypes and circular recombinant forms (CRFs), available at Los Alamos database (http://www.hiv.lanl.gov). Gaps were then removed from the final alignment. The phylogenetic tree was inferred using all of the sequences generated to ensure that there was no cross-contamination of samples. Maximum-likelihood analysis for phylogenetic tree inference was performed using the PAUP* package [34] . The transversion model (GTR?I?G) of nucleotide substitution was chosen using Modeltest v.3.7 implemented in PAUP* [35] as the best-fitting evolution model for tree reconstruction. The statistical robustness and reliability of the branching order within each phylogenetic tree were confirmed by a bootstrap analysis using 1000 replicates on a maximum-likelihood tree generated by PhyML [36] . Recombination among HIV-1 subtypes was assessed using SCUEAL [37] , COMET [38] , and SimPlot software [39, 40] . All sequences were analyzed for resistance mutations using the Stanford University HIV Drug Resistance Database (http://www.hivdb.stanford.edu). The nucleotide sequences analyzed are in the process of being submitted to GenBank.
Data analysis
The rate of successful amplification and sequencing for ViroSeq TM and the in-house method was used to evaluate the performance of the in-house assay. Drug resistance mutations in both pol regions (PR ad RT) as well as polymorphic changes in positions not related to resistance compared to HIV-1 HXB-2 as a reference strain were analyzed for each patient.
Sequences obtained by both assays were compared based on the analysis of amino acid substitutions at all positions in the PR (amino acids 1-99) and RT (amino acids 1-300) regions. The similarity between sequence pairs was evaluated by phylogenetic analysis following previously reported phylogenetic tree inference methods and by calculation of the pairwise genetic distance (estimated as the number of nucleotide substitutions per nucleotide site) in the MEGA version 4.1 package. Codons 1-99 in the PR region and 1-300 in the RT region were considered for both assays, including an overview analysis on the sequencing primer mismatch. The sequences obtained independently by both systems were analyzed for reproducibility of detection of amino acid mutations using the following criteria (as reported previously by Saravanan et al. [24] ): a. Concordant (if both assays gave the same result); b. Partially concordant (if mixture by one assay and not by the other); c. Discordant (if the two assays detected different amino acids).
Additionally, the same approach was used to estimate the capacity of both methods to detect drug resistance mutations. Specifically, 17 PR and 24 RT amino acid positions known to be related to drug resistance according to the Stanford University HIV Drug Resistance Database (http://www.hivdb.stanford.edu) were accurately analyzed for evaluation of concordance.
Results
Phylogenetic analysis
Phylogenetic analysis did not reveal any cross-contamination among the 188 samples that were successfully processed with both ViroSeq TM and the in-house assay. This analysis also revealed that CRF02_AG was the most prevalent strain (54.8%), followed by the subtypes A1 (12.8%), F2 (6.9%), D (6.4%), G (5.8%), the recombinant CRF11 (4.3%), and other HIV-1 non-B strains (1.6% CRF01_ AE, 1.6% A, 1.1% F2/G, 1.1% F1, 1.1% CRF02_AG/A1, 0.5% CRF37, 0.5% CRF13, 0.5% C, 0.5% CRF02_ AG/CRF01_AE, 0.5% CRF01_AE/G) (data not shown). With the exception of the ViroSeq TM positive standard, which was sequenced using both assays, there was no case of subtype B in the study population. Of the six amplified samples that were not using ViroSeq TM , five were successfully processed with the in-house assay, and phylogeny revealed subtypes A1 (2 samples, plasma viral load 4.35 and 4.85 log 10 RNA copies/ml), D (2 samples, plasma viral load 4.05 and 5.42 log 10 RNA copies/ml), and CRF02_AG (1 sample, plasma viral load 1.79 log 10 RNA copies/ml, which was below ViroSeq TM amplification threshold). Thus, amplification by ViroSeq TM was ineffective for subtypes A1 and D. The range of viremia for the samples processed by the in-house method was identical to that of samples processed with ViroSeq TM (1.79-6.96 log 10 RNA copies/ml), avoiding bias when comparing the amplification performance of the two methods.
An overview of the ViroSeq TM sequencing primers showed a good alignment with all the sequences, with the only exception being primer D, which aligned to 10 out of 70 (14.2%) sequences obtained with the ViroSeq TM system. The seven ''in-house'' sequencing primers also showed a good alignment to the sequences, without any significant mismatch. Analysis dedicated to the identification of drug-resistance-associated amino acid positions revealed a very high degree of concordance for the two methods. Specifically, among the 612 drug resistance positions analyzed in the PR region (17 amino acid positions 9 36 pairs of samples), no discordance was observed, and only three mutations (0.49%) were partially concordant in three different patients: two at position 54 and one at position 76 (Table 2) . On the other hand, among the 864 RT drug resistance positions analyzed (24 amino acid positions x 36 pairs of samples), a low degree of discordance (3/864, 0.35%) was observed at positions 74, 101 and 103. These discrepancies in the RT mutational profile were found in three patients. The rate of partial concordance between the two methods was 0.57% (5/864), found in four different patients at drug resistance position 69, 70 and 75. Interestingly, in all the cases of partial concordance, ViroSeq TM detected more viral mixtures than the in-house protocol. Analysis of drug resistance-associated positions in both (PR?RT) regions (1476; 41 amino acid 
In-house genotyping protocol for HIV-1 drug resistance testing 1239 positions 9 36 pairs of samples) revealed a very high degree of concordance, 99.25% (1465/1476), with no evidence of indeterminate results. Evaluation of the pairwise genetic distances between sequence pairs obtained by both methods showed a high similarity in the nucleotide outputs. The mean genetic distance between sequence pairs was 0.0003 for the PR region (ranging from 0 to 0.057) and 0.0002 for the RT region (ranging from 0 to 0.042).
Phylogenetic analysis confirmed that sequences of each sample generated with both assays clustered together with a high ([90%) bootstrap robustness, thus demonstrating homology in subtyping and fidelity in the reproducibility of the two protocols (Fig. 1) . Only a single sequence pair was not found to cluster together monophyletically using the bioinformatics tools used for phylogenetic tree construction.
Cost evaluation of the in-house assay A cost analysis was performed to evaluate the financial aspect potentially related to the use of the in-house protocol for monitoring drug-resistant HIV-1 strains. The overall cost per sample using this protocol was around 92 € compared to 217 € with ViroSeq TM , despite the common consumables used in both protocols (Table 3) . Coupled with its reliability and validity, as shown above, the low cost of this in-house protocol will therefore reduce to about half the cost for HIV genotyping, compared to the ViroSeq TM kit. This alternative could increase accessibility to surveillance of HIV-1 drug resistance in the health systems as well as access to routine clinical practices for medium to large population-based genotyping services, both in resource-limited and high-viral-genetic-diversity settings.
Discussion
With the increasing availability of generic HAART drugs in Cameroon, the establishment of an accurate, reproducible, and highly sensitive but also affordable assay for monitoring viral evolution and drug resistance of emerging strains in patients undergoing treatment is becoming a public-health priority. Indeed, accessibility to antiretroviral drugs without adequate monitoring may result in the rapid spread of drug-resistant HIV-1 strains. The in-house assay developed in this study represents a good alternative to the standard commercially available HIV-1 genotyping assays by reducing costs while maintaining the same specificity and sensitivity in detecting HIV-1 drug resistance mutations. More importantly, the in-house protocol reported here was found to have a high PCR sensitivity, with a large number of amplicons already produced in the first PCR step (64.1%). Furthermore, it was also able to sequence 98.7% of plasma samples with detectable viremia, even at very low values (1.79 log 10 RNA copies/ml), due to the use of a sensitive semi-nested PCR. These findings, in terms of reproducibility and capability of detecting drug-resistance-associated mutations, are similar to data reported by Saravanan et al. [24] . Particularly, drug-resistance mutations associated with treatment failure were identified perfectly using the ViroSeq TM kit and our in-house assay. Discordant mutations at drugresistance-associated positions were identified only in less than 0.3% of the overall studied population; their presence likely reflects the normal test-to-test variability or the prevalence of quasispecies [41] . An almost full mutational similarity between the pairs of sequences was obtained by both assays (the commercial and the in-house) in all 399 analysed amino acids encompassing the PR and RT regions (and not only restricted to drug resistance positions).
The in-house method has been shown to identify a wide spectrum of HIV-1 strains belonging to different subtypes (7 pure subtypes, 5 known CRFs, and 4 rare unclassified recombinant forms), using specific primers matching in highly conserved regions. The capacity to identify these subtypes was greater compared to other in-house antiretroviral drug resistance assays used previously in limited-resource settings. These previous in-house assays were restricted either to the sequencing of four pure subtypes (A1, B, C, D) and two known CRFs (CRF01_AE and CRF02_AG) in South Africa [25] or to three pure subtypes (B, C, D) in the case of the Indian study [24] . Therefore, the results indicate a highly successful sequencing performance using the in-house protocol in a context of high HIV-1 genetic diversity, as is found in sub-Saharan Africa [42, 43] .
Although sequence editing was more laborious and time-consuming with the in-house method, both protocols had very similar laboratory and usage characteristics. For instance, the required time scales for completion of both assays were quite similar (ViroSeq TM , 16 hours; in-house assay, 20 hours), with the second step PCR (semi-nested) constituting the time difference between the two methods. Therefore, personnel should be well trained to ensure appropriate analysis and a relevant resistance report with this in-house protocol.
Moreover, despite the high risk of cross-contamination with nested PCR [44] , results obtained in this study showed no event of this nature. Therefore, this finding proves that compliance with these laboratory criteria is a sufficient approach to ensure valid and reliable results in a standard molecular biology laboratory [45] . A contamination check also excluded the possibility of sample mix-up, thus suggesting that the unpaired sequences from the same sample were possibly due to an inaccurate identification of recombination using the bioinformatics tools.
Finally, it should be emphasized that the in-house assay costs approximately 50% less (92 €) than the ViroSeq TM kit (217 €), a cost that appears similar to the one reported with the in-house HIV-1 genotyping system developed by In-house genotyping protocol for HIV-1 drug resistance testing 1241
Saravanan et al. [24] ($100 vs. $230 for ViroSeq TM ). Therefore, the use of this low-cost assay can significantly improve the management of HIV-1 infection in countries with limited resources for medium and large populationbased genotyping services, representing a useful weapon against the spread of HIV-resistant strains [46] .
Further studies spanning a wider spectrum of viral loads, subtypes and known resistant HIV-1 isolates are necessary to better investigate the analytical sensitivity of this inhouse sequencing assay for the detection of drug resistance mutations.
In conclusion, the present study describes the validation of a new in-house HIV-1 genotyping system for plasma samples. The wider coverage of HIV-1 genetic diversity, together with its low cost, makes this in-house assay a suitable and affordable tool for resource-limited settings. Moreover, it represents an attractive alternative for HIV-1 drug resistance surveillance and for reducing the risk of selection of further drug-resistance-associated mutations in financially constrained public health systems.
